581 results about "Ce Antibody" patented technology

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.

Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.

A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided.

The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.

The invention relates to a method and apparatus for pre-hatch avian embryo sex determination. In particular, the invention relates to a non-invasive method and apparatus for in-ovo determining the sex of avian species while in the egg and allowing to sort the eggs into groups consisting primarily of either male or female embryos. The method comprises the steps of introducing into the egg an antibody designed to match with a sex specific antigen on the embryo, which antibody is labelled, allowing the labelled antibody to migrate to and bind with the sex specific antigen on the embryo, detecting binding of the labelled antibodies on the embryo using detection means positioned outside of the egg.

Relating to the technical field of pharmaceutical preparations, the invention provides an antibody composition preparation composed of Trastuzumab and Pertuzumab. The antibody composition preparation has better tumor treatment activity. Compared with the independent treatment of Trastuzumab and Pertuzumab, the composition preparation shows a synergistic effect of the two antibodies, and can reach a tumor control rate of 92.43%. And the preparation provided in the invention has better stability, thus being in favor of long-term preservation of the antibody composition preparation. The antibody composition preparation provided in the invention is applicable to preparation of drugs treating diseases or symptoms suited to anti-HER2 antibody therapy. During application, the antibody composition preparation disclosed in the invention is used with a chemotherapeutic agent jointly or sequentially.

The invention discloses a monoclonal antibody for resisting novel coronavirus or a derivative thereof. The monoclonal antibody comprises antigen complementary determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region, wherein the CDR1, the CDR2 and the CDR3 are amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 6 and SEQ ID NO: 7 respectively; the antigen complementary determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region are amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 respectively. The invention further discloses a preparation process of the antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region.

The invention discloses a composite IgY antibody for resisting COVID-19 and SARS. The antibody is prepared by the following method: constructing a recombinant antigen of SARS-CoV-2 and SARS-CoV; preparing an immune preparation with the recombinant antigen to immunize egg-producing birds, and obtaining the specific composite IgY antibody from the immunized eggs. A spray prepared by the antibody canbe used for broad-spectrum killing of SARS-CoV-2 and SARS-CoV, and is suitable for spraying on nasal cavity, oral cavity, skin and other parts. The antibody preparation has a specific virus neutralizing effect, can effectively control infection sources, protect susceptible people, disinfect and protect first-line medical staff and prevent spread of SARS-CoV-2.

The invention discloses the production method and use for imidacloprid artificial hapten, artificial antigen and specific antibody, wherein the production method comprises, using imidacloprid (1-(6-chlorine-3-picolyl)-N-nitro-2-imidazoline imine) as raw material for reaction with 3-mercaptopropionic acid under alkaline condition, thus synthesizing hapten 1-(6-(2-carboxyethyl) sulfo-3-picolyl)-N-nitro-2-imidazoline imines (IM), then coupling with proteins through carbodiimide method and mixed anhydride method to prepare artificial antigens (immunogens and peridium antigens).

Disclosed in the present invention are a mouse monoclonal antibody for antagonizing and inhibiting the binding of a programmed death-1 (PD-1) to the ligand thereof, and the heavy chain variable region and light chain variable region amino acid sequences thereof. Also disclosed in the present invention is a DNA molecule nucleotide sequence encoding the heavy chain variable region and light chain variable region of the antibody. Also disclosed in the present invention are a method for preparing a human-mouse chimeric antibody of the antibody and derivatives thereof, and the use thereof in PD-1 protein detection.

The invention discloses an antibody or an antigen binding part thereof binding to human TSLP, a nucleic acid molecule encoding the antibody or the antigen binding part of the antibody, a vector containing the nucleic acid molecule, a host cell containing the nucleic acid molecule or the vector, a method for preparing and purifying the antibody, and an application of the antibody or the antigen binding part of the antibody.

The invention discloses a process for preparing Quinclorac artificial semiantigen, artificial antigen, specific antibody and use thereof, wherein the preparation comprises, subjecting the dichloroquine (3,7-dichlorine-8-quinoline carboxylic acid) to sulfoxide chlorinated acylation, reacting with reanal and aminocaproic acid, thus obtaining semiantigen 4-(3,7-dichlorine-8-quinolineformyl) reanal or 6-(3,7-dichlorine-8-quinolineformyl) aminocaproic acid (QB or QC).

The present invention provides a humanized form of antibody 340, which can be obtained from the cell line deposited at ECACC with accession number 97021428. This antibody was found to be more potent than murine antibody 340 in killing cells. Nucleic acids encoding the antibodies are also provided, as well as the use of the antibodies in medicine, especially in the treatment of cancer.

The invention discloses a human single chain antibody and application of an antitumor vascular endothelium marker molecule 8-cell outer region. The amino acid sequence of the single chain antibody is SEQ ID NO:1. The amino acid sequence of a heavy chain variable region of the antibody is SEQ ID NO:2, and the amino acid sequence of a light chain variable region of the antibody is SEQ ID NO:3. The human single chain antibody of the antitumor vascular endothelium marker molecule 8-cell outer region can be applied to early diagnosis and target treatment of tumor.